Le 27 février 2016, CATIE a eu la chance d’animer un autre institut d’apprentissage lors du 5e Symposium canadien sur le VHC qui s’est tenu à Montréal, Québec. Les instituts d’apprentissage constituent des occasions passionnantes d’échanger des connaissances et de renforcer les capacités pour les intervenants œuvrant dans le domaine de la prévention, du traitement et des soins liés à l’hépatite C à travers le Canada. Nos 15 rapporteurs se s ont renseignés sur la recherche actuelle et ont travaillé ensemble afin de résumer l’information et de la distribuer au sein de leur communauté.
Dans la première partie de cette série de deux blogues, deux rapporteurs font un retour sur leur expérience à l’institut d’apprentissage.
In Canada today, prisoners who inject drugs need to share needles, many of which have been used numerous times by other prisoners. Without access to sterile injection equipment, rates of HIV and hepatitis C virus are much higher behind bars than in the broader community. Prison-based needle and syringe programs (PNSPs) are an important way to address this public health problem, yet Canadian correctional authorities often claim they won’t work. A recent study demonstrates that PNSPs are indisputably feasible in Canada and should be implemented now.
A new report, On Point: Recommendations for Prison-Based Needle and Syringe Programs in Canada, outlines the findings of a two-year study that involved consultation with a range of diverse stakeholders, including former prisoners themselves. The research was conducted by representatives from the Department of Criminology at Ryerson University, PASAN (a community-based AIDS service organization that provides community development, education, and support to prisoners and ex-prisoners in Ontario), and the Canadian HIV/AIDS Legal Network (one of the world’s leading organizations tackling the legal and human rights issues related to HIV).
My daughter has a smartphone cover that says: “We’re all mad here”. It’s from Alice in Wonderland. I like it; and when it comes to hepatitis C treatment and pricing, it’s quite on point.
In 2014, Canada and the rest of the world turned a miraculous corner – a cure for viral hepatitis C was on the market. Wonderful and amazing. Why? Well, viral hepatitis C is the only chronic viral infection that now has a cure – that is, a cure for virtually everyone, with a cure rate of 95 per cent.
Hepatitis C is curable, reads the script; time and time again I hear this said, have read it, and say it myself. This is great news and a reality for more people than ever before.
Does this mean that the job is done? I suppose it depends on one’s perspective. As I listened to members of the science research community speak recently, it is “done and dusted.” “Problem solved,” the headlines will read. Okay, maybe no headlines but a mention on page 4 with a minor piece in the late evening news, even though this may be the biggest news in medical science in decades.
I had the honour of attending the recent and first-ever World Hepatitis Summit in Glasgow, Scotland from September 2-4, 2015. What a treat it was to come together with hundreds of other people from around the globe to discuss the often ignored health issue of viral hepatitis. Here I was, “amongst my people,” talking like crazy about viral hepatitis as if it were important or something. How new and novel, because here in Canada viral hepatitis is the conversation we never have, despite the fact that at least 250,000 Canadians are affected by it.
Le Blogue de CATIE présente des perspectives et opinions des personnes et organismes qui travaillent ou collaborent bénévolement à la réponse du Canada au VIH et à l’hépatite C.